Long Term Effect of Oxaliplatin Treatment in Cancer Survivors
Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
This project will evaluate the neurotoxic effects of oxaliplatin. Oxaliplatin is considered
the most neurotoxic chemotherapy, and at the origin of peripheral neuropathies. These
neuropathies remain a problem in oncology because currently no prevention strategy has proved
effective and only duloxetine seems to have a therapeutic benefit in improving symptoms. In
the case of oxaliplatin, neuropathy forced oncologists to reduce the dose or to stop the
chemotherapy, potentially degrading the oncological prognosis.
Objective of this study will be to assess, on a large number of patients (n> 500) who
completed adjuvant chemotherapy (FOLFOX), the intensity of neuropathic disorders out of 5
years after the end of chemotherapy. Furthermore, this study should enable an assessment of
the relationship between the intensity of neuropathy and comorbidities, such as anxiety and
depression and health related quality of life of patients.